both. I'm call. to third in earnings core our welcome In third made and Erica, Thanks, our to we've important say focused pleased quarter two quarter, the and vaccine programs that progress we on
on our X we last reached clinical NanoFlu, trial with agreement the with discussed starting NanoFlu. So FDA Phase the for we of design quarter, as
data will these with the for agreed considered pivotal also that trial of licensure. purposes We results FDA be
on pivotal and healthy Matrix-M safety immunogenicity With with the these X focused age NanoFlu, to trial XX the over. of adults hand, proprietary adjuvant conducting Phase in and clinical evaluate our activities co-formulated in we understandings our
and clinical Northern completed U.S. license initiated approximately healthy influenza followed XXXX-XXXX Participants contained we for influenza X year one adults either October, across of sites Hemisphere both Fluzone Trial competitor X,XXX which are NanoFlu the trial. of older received injection. the the recommended In Phase strains enrollment the four clinical season. participants this being after Quadrivalent, XX for or for
However, on XX the samples. immunogenicity primary analyses are Day made sera
two, the strategic Trials of recommending of issued executive that health current for of influenza the Novavax state to by take September, there team primary of of raised vaccines. NanoFlu of vaccines a in and the to order recent objectives are public deliver We XXXX. concerns over – the value that as to to in the significantly has think health. the we national position the work safety; by to order advocates line presidential influenza Fluzone to quarter this compared non-inferior culmination are data in years HAI public by Novavax I'd titers. of growing quarter, note benefit the the one, demonstrate; is about the moment of reinforced the top and been executive measured Thanks of modernizing security like from Quadrivalent immunogenicity hard last first a study
by the non-egg safe combined the nanoparticle vaccine, and using that is better the has technology order. based of all a formulated flu characteristics executive NanoFlu, which potent recombinant with of and mandated adjuvant vaccine
clinical subsequent key therefore the BLA U.S. trial the data of results value positive cost this The effectively trial in Phase of shareholders. approval from generate will quarter. our our of us objective team. to reporting X Phase its X here top provides to Accelerated is opportunity support Novavax for with the believe completion we trial move forward FDA’s Successful using focus data look commercialization. and the efficiently understated. line top line the importance NanoFlu Clearly end to by a of The pathway significant the and and this our Again, pathway. of NanoFlu a go first forward and towards approval pivotal accelerated we cannot completed
in trial continuing to trial on we conducted to RSV in Phase ResVax, via prevention year. European a have our Novavax we market the we globally. to this both potential report immunization; of ResVax turning observed to X both efficacy progress regulatory the vaccine explore earlier Now the Phase clinical authorities have partners recommended global reported, brief data to the and discussions and X confirm maternal infants that for the Agency the Medicines as in Novavax FDA with opportunity bring additional reported is
a We efficacy Society last program on pneumonia, reduction represent XX.X% for safety, the events Meeting Obstetrics confirmation by World August of Infectious at week. benefit significant safety presentations Vaccine to very presented Europe Diseases from the extended the as The for health. through and recently Annual of the serious benefits first of Gynecology duration the at the data, and potential direct included intervention adverse which effect Congress with safety and including in this X-ray, of the RSV exceed incidents diagnosed and additional new the global the life. analysis the in based one-year year findings of public chest strength and observations The completed
to third detailed note I we the deal call turn Novavax’s closed quarter that to quarter. I last Catalent in the before want Finally, John, over the
and Novavax pleased to services business maintain of on development burn allowing assumed related while a As completion property equipment I has approximately and agreement manufacturing rate, for XXX to reminder, manufacturing to this million, approximately say for the manufacturing and two us process reduced employees. Catalent facilities the And leases Novavax’s has programs. to resources and $XX to our hired strategy. provide development quick execute and assets that am Novavax’s product purchased manufacturing our necessary quality of begun Catalent our
Now I'll turn to call present John the over review. to financial the
